“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD

“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD

Claus Vogelmeier,1 Heinrich Worth,2 Roland Buhl,3 Carl-Peter Criée,4 Nadine S Lossi,5 Claudia Mailänder,5 Peter Kardos6 1Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Member of the German...

Full description

Bibliographic Details
Main Authors:	Vogelmeier C, Worth H, Buhl R, Criée C, Lossi NS, Mailänder C, Kardos P
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-02-01
Series:	International Journal of COPD
Subjects:	COPD exacerbations chronic obstructive pulmonary disease health related quality of life inhaled steroids
Online Access:	https://www.dovepress.com/ldquoreal-liferdquo-inhaled-corticosteroid-withdrawal-in-copd-a-subgro-peer-reviewed-article-COPD

Similar Items

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
by: Buhl R, et al.
Published: (2018-08-01)

A year in the life of German patients with COPD: the DACCORD observational study
by: Buhl R, et al.
Published: (2016-07-01)

Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice
by: Cataldo D, et al.
Published: (2018-07-01)

Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms
by: Avdeev S, et al.
Published: (2019-06-01)

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population
by: Vestbo J, et al.
Published: (2019-04-01)

A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
by: Micheletto C, et al.
Published: (2019-09-01)

Lack of Association between Inhaled Corticosteroid Use and the Risk of Future Exacerbation in Patients with GOLD Group A Chronic Obstructive Pulmonary Disease
by: Sun Hye Shin, et al.
Published: (2022-05-01)

A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease
by: Marc Miravitlles, et al.
Published: (2017-11-01)

“Breathing New Life Into Chronic Obstructive Pulmonary Disease (COPD)” – Results From An Online Survey Of UK Patients
by: Titmarsh S, et al.
Published: (2019-12-01)

A Prediction Scoring Model for the Effect of Withdrawal or Addition of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease
by: Lee JH, et al.
Published: (2023-02-01)

Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain
by: Neches García V, et al.
Published: (2022-09-01)

Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study
by: Claus F. Vogelmeier, et al.
Published: (2022-05-01)

Blood eosinophil percentage as a predictor of response to inhaled corticosteroid in bronchiectasis
by: Wang Chun Kwok, et al.
Published: (2023-06-01)

An assessment of asthma exacerbations in pediatric patients using a long-acting B2-agonist plus inhaled corticosteroid versus an inhaled corticosteroid alone
by: Yousif S. Alakeel, et al.
Published: (2022-03-01)

Non-adherence to inhaled corticosteroids and the risk of asthma exacerbations in children
by: Vasbinder EC, et al.
Published: (2016-04-01)

Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey
by: Miravitlles M, et al.
Published: (2022-07-01)

Protective effect of inhaled corticosteroid on children with asthma with Mycoplasma pneumoniae pneumonia
by: Bing Wei, et al.
Published: (2022-08-01)

Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History
by: Andrea S. Melani, et al.
Published: (2024-02-01)

Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain
by: Miravitlles M, et al.
Published: (2022-01-01)

Compare the Effect of Inhaled Corticosteroids and Systemic Corticosteroids on Sputum Microbiome of AECOPD
by: Nan Ma, et al.
Published: (2021-02-01)

“NEWS2” as an Objective Assessment of Hospitalised COPD Exacerbation Severity
by: Stone PW, et al.
Published: (2022-04-01)

Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis
by: Lotte C. Terpstra, et al.
Published: (2022-12-01)

Association Between Patient Preference for Inhaler Medications and Asthma Outcomes
by: Nakanishi Y, et al.
Published: (2022-10-01)

The BATTLE study: Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. Study protocol of a double blind, randomized, placebo-controlled trial: study protocol
by: L.C. Terpstra, et al.
Published: (2022-12-01)

FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy
by: González-Torralba F, et al.
Published: (2022-05-01)

Estimating Inhaled Corticosteroid Exposure from Short-Acting β2-Agonist–Inhaled Corticosteroid Rescue
by: Lugogo N, et al.
Published: (2023-05-01)

The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes
by: Bosnic-Anticevich S, et al.
Published: (2016-12-01)

High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis
by: Archontakis Barakakis P, et al.
Published: (2023-04-01)

“Frequent exacerbator” is a phenotype of poor prognosis in Japanese patients with chronic obstructive pulmonary disease
by: Tomioka R, et al.
Published: (2016-02-01)

COPD Patients’ Behaviour When Involved in the Choice of Inhaler Device
by: Sorin Bivolaru, et al.
Published: (2023-05-01)

A clinical prediction model for hospitalized COPD exacerbations based on “treatable traits”
by: Yii ACA, et al.
Published: (2019-03-01)

The dose of inhaled corticosteroids in patients with COPD: when less is better
by: Izquierdo JL, et al.
Published: (2018-10-01)

Identifying critical inhalation technique errors in Dry Powder Inhaler use in patients with COPD based on the association with health status and exacerbations: findings from the multi-country cross-sectional observational PIFotal study
by: Janwillem Kocks, et al.
Published: (2023-08-01)

Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease
by: Sicras Mainar A, et al.
Published: (2019-09-01)

Inhaled Corticosteroids Is Not Associated with the Risk of Pneumonia in Asthma
by: Ye Jin Lee, et al.
Published: (2023-07-01)

Inhaled Corticosteroids and the Lung Microbiome in COPD
by: Holly R. Keir, et al.
Published: (2021-09-01)

Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler versus multiple-inhaler triple therapy: A prospective observational study in China
by: Ling Lin, et al.
Published: (2023-03-01)

Exacerbations in COPD patients treated with Inhaled Corticosteroids/Long-acting β2 agonists combinations, switching to another combination drugs or inhaler device: A “real – world” study
by: Diego Sangiorgi, et al.
Published: (2017-01-01)

Role of inhaled antibiotics in children and adolescents with cystic fibrosis: Experience from the tertiary care center
by: Danish Abdul Aziz, et al.
Published: (2022-01-01)

Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study
by: Helgo Magnussen, et al.
Published: (2021-01-01)